ARQ 197

DRUG14 trials

Sponsors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Kyowa Kirin Co., Ltd., National Cancer Institute (NCI)

Conditions

Advanced Hepatocellular CarcinomaAlveolar Soft Part Sarcoma (ASPS)CancerCancer, Advanced Solid TumorsCirrhosisClear Cell Sarcoma (CCS)Gastric CancerHealthy

Phase 1

ARQ 197 in Subjects With Metastatic Solid Tumors

CompletedNCT00302172

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Cancer, Tumor

Start: 2006-01-31Target: 78Updated: 2009-08-26

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

CompletedNCT00612209

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Cancer, Advanced Solid Tumors

Start: 2007-04-30End: 2010-02-28Updated: 2012-07-23

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

CompletedNCT00612703

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Cancer

Start: 2008-02-29Updated: 2012-07-23

Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers

CompletedNCT00658554

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Healthy

Start: 2008-04-30End: 2008-06-30Updated: 2008-06-19

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

CompletedNCT00802555

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Cirrhosis, Hepatocellular Carcinoma

Start: 2009-01-31End: 2011-12-31Updated: 2012-07-12

Pazopanib and ARQ 197 for Advanced Solid Tumors

CompletedNCT01468922

National Cancer Institute (NCI)Solid Tumor

Start: 2012-01-23End: 2016-02-11Updated: 2022-07-01

Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

CompletedNCT01656265

Kyowa Kirin Co., Ltd.Advanced Hepatocellular Carcinoma

Start: 2012-07-31End: 2014-03-31Updated: 2017-03-03

Phase 2

A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma

CompletedNCT00558207

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Pancreatic Neoplasms

Start: 2007-11-30End: 2008-04-30Updated: 2013-02-25

Phase 2 Study in Patients With MiT Tumors

CompletedNCT00557609

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS), Renal Cell Carcinoma (RCC)

Start: 2007-10-31End: 2011-02-28Updated: 2013-02-08

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT00777309

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Non Small Cell Lung Cancer

Start: 2008-09-30End: 2011-08-31Updated: 2013-02-28

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

CompletedNCT00988741

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Unresectable Hepatocellular Carcinoma

Start: 2009-09-30End: 2012-03-31Updated: 2013-02-28

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

WithdrawnNCT01070290

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Gastric Cancer

Updated: 2014-01-07

Study of ARQ 197 Monotherapy

CompletedNCT01152645

Kyowa Kirin Co., Ltd.Gastric Cancer

Start: 2010-06-30End: 2011-08-31Updated: 2017-03-15

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

CompletedNCT01580735

Kyowa Kirin Co., Ltd.Non-small-cell Lung Cancer

Start: 2012-05-31End: 2015-04-30Target: 40Updated: 2015-08-18

Related Papers

Immune cell transcriptional profiles from pre-vaccination peripheral blood predict immune response to preventative MUC1 cancer vaccine.

2025-08-051 citations

Abstract 6537: Single cell transcriptomics uncovers cellular and molecular differences in PBMCs of responders and non-responders to the MUC1 cancer vaccine given in the preventative setting

Cancer Research2023-04-04

Abstract A002: Evidence of pazopanib-induced epithelial-mesenchymal transition (EMT) in human tumors

Molecular Cancer Therapeutics2018-01-01

Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors.

Journal of Clinical Oncology2016-05-204 citations

Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2016-02-017 citations

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

ESMO Open2016-01-0140 citations

Phase II study of erlotinib plus tivantinib in patients with <i>EGFR</i>-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy.

Journal of Clinical Oncology2014-05-205 citations

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

2012-11-20436 citations